肺肉瘤样癌免疫治疗的研究进展

Advances in immunotherapy for pulmonary sarcomatoid carcinoma

肺肉瘤样癌(PSC)是一种罕见的含有肉瘤样成分或肉瘤样分化的低分化非小细胞肺癌(NSCLC),在所有肺部肿瘤中所占比例不足1%。PSC相较其他类型的NSCLC生物学行为更具侵袭性,极易转移,且早期手术后复发率较高。其对传统治疗模式耐药性更强,导致其预后较其他NSCLC更差。近年来,免疫治疗的广泛应用为PSC患者带来了长期生存的可能性。

Pulmonary sarcomatoid carcinoma(PSC)is a rare,poorly differentiated non-small cell lung cancer(NSCLC)that contains sarcomatoid components or sarcomatoid differentiation,and accounts for less than 1%of all lung tumors.Compared to other types of NSCLC,PSC has more invasive biological behavior,is prone to metastasis,and has a higher recurrence rate after early surgery.Its greater resistance to traditional treatments leads to a poorer prognosis compared to other NSCLCs.Immunotherapy offers the possibility of long-term survival for PSC patients.